Y-mAbs Therapeutics, Inc.
YMABDrugs in Pipeline
8
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
GM-CSF + Naxitamab
Neuroblastoma
Hu3F8 With GM-CSF
Neuroblastoma
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Neuroblastoma
Hu3F8
Neuroblastoma
Naxitamab
Neuroblastoma
131 I-omburtamab
Desmoplastic Small Round Cell Tumor
humanized anti-GD2 antibody
Recurrent Osteosarcoma
Omburtamab I-131
Recurrent Medulloblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GM-CSF + Naxitamab | Phase 2 | Neuroblastoma | - | - |
Hu3F8 With GM-CSF | Phase 2 | Neuroblastoma | - | - |
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | Phase 2 | Neuroblastoma | - | - |
Hu3F8 | Phase 2 | Neuroblastoma | - | - |
Naxitamab | Phase 2 | Neuroblastoma | - | - |
131 I-omburtamab | Phase 2 | Desmoplastic Small Round Cell Tumor | - | - |
humanized anti-GD2 antibody | Phase 2 | Recurrent Osteosarcoma | - | - |
Omburtamab I-131 | Phase 2 | Recurrent Medulloblastoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Y-mAbs Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Y-mAbs Therapeutics, Inc.'s (YMAB) pipeline across Phase 2. Its lead program is GM-CSF + Naxitamab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Y-mAbs Therapeutics, Inc.'s next FDA catalyst?→
Y-mAbs Therapeutics, Inc.'s (YMAB) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track YMAB biotech catalysts?→
Add YMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Y-mAbs Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.